The combination of PI3K-Akt-mTOR inhibition and metabolic targeting is now under investigation for other cancers,30,31 and our results suggest that this combined strategy should be further considered in AML, but possibly only for selected subsets of patients. This evidence concerns the gene AKT1 and cancer.